NCT04019184View on ClinicalTrials.gov

Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

February 13, 2020

Study Completion Date

May 13, 2020

Conditions
Cardiac SurgeryAcute Kidney Injury
Interventions
DRUG

L-Alanyl/L-Glutamine

Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug

DRUG

Placebo

Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo

Trial Locations (1)

48149

University Hospital Münster, Münster

Sponsors

Collaborators (1)

Fresenius Kabi
All Listed Sponsors
collaborator

Fresenius Kabi

INDUSTRY

collaborator

IZKF (Interdisciplinary Centre for Clinical Research (IZKF), Muenster)

UNKNOWN

lead

University Hospital Muenster

OTHER

NCT04019184 - Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine | Biotech Hunter | Biotech Hunter